|
Opening Session
|
Mr Geoff Adams-Spink "Important of pharmacovigilance: lessons from the Thalidomide
tragedy"
Prof Lolkje de Jong-van den Berg "EUROmediCAT: working towards an European
Reproductive Pharmacovigilance System
|
|
Introduction Session
|
Dr Maria Loane "The EUROmediCAT Database"
|
|
Session 1:
Antidiabetics
in Pregnancy
|
Dr Rachel Charlton "Use of healthcare databases for studying drugs in pregnancy - the
example of antidiabetic drugs: EUROmediCAT results"
Dr Hao Wang "Risk of congenital anomalies after exposure to insulin analogs compared
with human insulin in diabetic women: EUROmediCAT results"
|
|
Panel Discussion
|
Dr Belma Malanda - comments in relation to session 1a;
Dr Belma Malanda - comments in relation to session 1b
Dr Margery Morgan - comments in relation to session 1
Prof Gerard Visser - comments in relation to session 1
Prof Ewa Wender-Ozegowska - comments in relation to session 1
|
|
Session 2:
Antiepileptics
in pregnancy
|
Prof Lolkje de Jong-van den Berg "Antiepileptic drugs: use and safety: EUROmediCAT
results"
Dr John Craig "EURAP and anti-epileptic drug safety monitoring"
|
|
Panel Discussion
|
Dr Renzo Guerrini - comments in relation to session 2
Prof Joanna Jedrzejczak - comments in relation to session 2
Dr Laura Yates - comments in relation to session 2
|
|
Session 3:
Antidepressants in
pregnancy
|
Dr Rachel Charlton "The use of SSRIs in pregnancy: EUROmediCAT results"
Dr Marian Bakker "Linking congenital anomaly registries with prescription data:
EUROmediCAT results
Prof Helen Dolk "Risk of congenital anomalies in relation to SSRI use in pregnancy:
EUROmediCAT results
|
|
Panel Discussion
|
Dr Heli Malm - comments in relation to session 3
Dr Irene Petersen - comments in relation to session 3
Prof Janusz Rybakowski - comments in relation to session 3
|
|
Session 4:
Antiasthmatics in
pregnancy
|
Prof Kari Klungsoyr "Antiasthmatic drug use in pregnancy: EUROmediCAT results"
Dr Ester Garne "Risk of congenital anomalies in relation to antiasthmatic use in pregnancy:
EUROmediCAT results
|
|
Panel Discussion
|
Prof Barbara Rogala - comments in relation to session 4
|
|
Session 5:
Prevention of
exposure to
teratogenic drugs
|
Prof Marlene Sinclair "Implications of internet use by pregnant women and drug safety
recommendations: EUROmediCAT results
Dr Christof Schaefer "The role of Teratogen Information Systems in Europe"
Dr Francois Houyez "Pregnancy exposure to orphan medicinal products"
|
|
Panel Discussion
|
Prof Vincenzo Bettoli - comments in relation to session 5
Dr Ineke Crijns - comments in relation to session 5
Dr Laura Yates - comments in relation to session 5
|
|
Session 6:
Signal detection
|
Dr Johannes Michiel Luteijn "Signal detection using congenital anomaly registry data"
Dr Joanne Given "New signals from EUROmediCAT"
|
|
Panel Discussion
|
Dr David Prieto - comments in relation to session 6
Dr Jennita Reefhuis - comments in relation to session 6
Dr Kristina Star - comments in relation to session 6
|
|
Session 7:
Recommendations
for reproductive
pharmacovigilance
in Europe
|
Prof Helen Dolk "Building a sustainable reproductive pharmacovigilance system -
recommendations from EUROmediCAT
Prof Corinne de Vries "Building a sustainable reproductive pharmacovigilance system -
the view from EMA
|
|
Panel Discussion
|
Mr Geoff Adams-Spink - comments in relation to session 7
Dr Kari Furu - comments in relation to session 7
Dr Christof Schaefer - comments in relation to session 7
|